EQS-Adhoc

Cosmo announces the start of trading of its shares on XETRA

EQS Group-Ad-hoc: Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous Cosmo announces the start of trading of its shares on XETRA 19-Apr-2021 / 06:00 GMT/BST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Dublin, Ireland - 19 April 2021: Shares of Cosmo Pharmaceuticals NV ('Cosmo') (SIX: COPN), which have traded on the Swiss Stock Exchange since 2007, will now also trade on XETRA in Frankfurt, Germany. Trading will commence today, Monday, at 9:00am CEST under tickersymbol C43. COSMO PHARMACEUT. EO-,26 ISIN: NL0011832936 | WKN: A2AJ68 | Ric: C43 | Type: Equity. The listing on XETRA, Germany's most important stock exchange, is aimed at providing easier access to European investors, significantly improving the visibility of the Company on the capital markets and increasing the overall liquidity in the trading of Cosmo's shares.

Cosmo has appointed ODDO BHF Corporates & Markets AG, market leader in Germany, as Designated Sponsor. Designated Sponsors provide additional liquidity in the electronic trading system XETRA by obliging themselves to set binding bid and ask limits (so-called quotes) in the order book for the respective managed assets in continuous trading and auctions. 

Cosmo recently announced US Food and Drug Administration (FDA) approval of GI GeniusTM, the first device approved by the FDA that uses artificial intelligence to help detect potential signs of colon cancer. GI GeniusTM is already approved in Europe, Australia, Israel and the United Arab Emirate and will be distributed worldwide under an exclusive distribution agreement with Medtronic. 

In 2020, Cosmo had revenues of €60.9 million, an operating profit of €6.9 million and delivered a cashflow from operating activities of €10.1 million. During 2020, Cosmo received European approval for Methylene Blue MMX(R) for the visualization of colorectal lesions during colonoscopies and received FDA approval for BYFAVO(TM) for use in procedural sedation. The market value of Cosmo's stake in Cassiopea SpA (SIX: SKIN), equity investments, treasury shares, loans and cash & liquid investments at 31 December 2020 was €624.6 million and equity was €400.1m.